Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period

Several virus-neutralizing monoclonal antibodies (mAbs) have become new tools in the treatment of the coronavirus disease (COVID-19), but their effectiveness against the rapidly mutating virus is questionable. The present study investigated the effectiveness of Tixagevimab/Cilgavimab and Regdanvimab...

Full description

Bibliographic Details
Main Authors: Daria S. Fomina, Marina S. Lebedkina, Anna A. Iliukhina, Anna V. Kovyrshina, Artem Y. Shelkov, Sergey S. Andreev, Anton A. Chernov, Inna V. Dolzhikova, Tatyana S. Kruglova, Gerelma V. Andrenova, Amir I. Tukhvatulin, Dmitry V. Shcheblyakov, Alexander V. Karaulov, Maryana A. Lysenko, Denis Y. Logunov, Alexander L. Gintsburg
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Immunology
Subjects:
neutralizing antibodies
Tixagevimab/Cilgavimab
Regdanvimab
COVID-19
omicron
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1259725/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1259725/full

Similar Items